Until now, pharmaceutical treatments for type 2 diabetes consist of biguanides, sulfonylureas, and alpha-glucosidase inhibitors, in addition to semaglutide and tirzepatide, which were recently included in the treatment of type 2 diabetes and obesity. The gene discussed is GAA; the disease is type 2 diabetes mellitus.